C.F.R. homeSearch C.F.R.
C.F.R.Title 21Chapter I—Food and Drug Administration, Department of Health and Human ServicesSubchapter H—Medical DevicesPart 814—Premarket Approval of Medical DevicesSubpart A—General

21 C.F.R. § 814.1 (2026)

Scope

Edition and currency
eCFR text as of Sept. 29, 2026. The text is the edition Syfert holds; for a past event, check the version in force on that date.
Other sources
CURRENTeCFR text as of Sept. 29, 2026 cited 1994–2025 44citing cases
At a glance

Courts have cited this section in 44 opinions since 1994, 1 of them in the last five years. The most litigated part is subsection (c)(1) (2 cases).

(a) This section implements sections 515 and 515A of the act by providing procedures for the premarket approval of medical devices intended for human use.

(b) References in this part to regulatory sections of the Code of Federal Regulations are to chapter I of title 21, unless otherwise noted.

(c) This part applies to any class III medical device, unless exempt under section 520(g) of the act, that:

(1) Was not on the market (introduced or delivered for introduction into commerce for commercial distribution) before May 28, 1976, and is not substantially equivalent to a device on the market before May 28, 1976, or to a device first marketed on, or after that date, which has been classified into class I or class II; or

(2) Is required to have an approved premarket approval application (PMA) or a declared completed product development protocol under a regulation issued under section 515(b) of the act; or

(3) Was regulated by FDA as a new drug or antibiotic drug before May 28, 1976, and therefore is governed by section 520(1) of the act.

(d) This part amends the conditions to approval for any PMA approved before the effective date of this part. Any condition to approval for an approved PMA that is inconsistent with this part is revoked. Any condition to approval for an approved PMA that is consistent with this part remains in effect.

[51 FR 26364, July 22, 1986, as amended at 79 FR 1740, Jan. 10, 2014]
The 20 cases that cite 21 C.F.R. § 814.1 most heavily, weighted by court and treatment. RelevanceNewestTreatment
1
GREENMedtronic, Inc. v. Lohr, 518 U.S. 470 (1996).
cites § 814.1 2×cited by 2,268 cases
Where it cites § 814.1
“§ 360e(b)(1)(A); 21 CFR § 814.1 (c)(1) (1995). [3] Second, to prevent manufacturers of grandfathered devices from monopolizing the market while new devices clear the PMA hurdle, and to ensure that improvements to existing devices can be rapidly introduced into the market, the…”
The case’s holding
Federal medical device regulations do not preempt state common-law claims based on general duties of care that do not impose specific, device-specific requirements.
Later courts cite it for
“because the states are independent sovereigns in our federal system, we have long presumed that congress does not cavalierly pre-empt state-law causes of action.” · 96 citing courts
2
GREENJoseph Mink v. Smith & Nephew, Inc., 860 F.3d 1319 (11th Cir. 2017).
cites § 814.1 1×cited by 68 cases
Where it cites § 814.1
“21 C.F.R. § 814.1 . Premarket approyal is a rigorous process of federal review that evaluates a medical device’s safety and effectiveness.”
The case’s holding
A state law claim is not preempted if the plaintiff alleges a breach of a well-recognized duty that parallels federal requirements.
Later courts cite it for
“to make it through, a plaintiff has to sue for conduct that violates a federal requirement (avoiding express preemption), but cannot sue only because the conduct violated that federal requirement (avoiding implied preemption).” · 11 citing courts
3
GREEND'Agostino v. EV3, Inc., 845 F.3d 1 (1st Cir. 2016).
cites § 814.1 1×subsections: (c)cited by 64 cases
Where it cites § 814.1
“See 21 C.F.R, § 814.1(c). During that process, the device manufacturer supplies the FDA with extensive information regarding the device — including its design, manufacturing, packing, labeling, and testing — to satisfy the agency that the device is safe and effective.”
The case’s holding
A fraudulent inducement claim under the False Claims Act requires alleging that the defendant's conduct caused the government to make a payment or forfeit money owed.
Later courts cite it for
“to rule otherwise would be to turn the fca into a tool with which a jury of six people could retroactively eliminate the value of fda approval and effectively require that a product largely be withdrawn from the market even when the fda itself sees no reason to do so.” · 5 citing courts
4
GREENNorth Am. Med. Corp. v. Axiom Worldwide, Inc., 522 F.3d 1211 (11th Cir. 2008).
cites § 814.1 1×cited by 162 cases
Where it cites § 814.1
“81 (a)(1) (2006), with 21 C.F.R. § 814.1 (c) (2006). As such, Axiom’s statements that the DRX 9000 is FDA “approved” are literally false.”
The case’s holding
Using a competitor's trademarks in website meta tags constitutes a use in commerce in connection with advertising if the use causes a likelihood of source confusion.
Later courts cite it for
“although ebay dealt with the patent act and with permanent injunctive relief, a strong case can be made that ebay's holding necessarily extends to the grant of preliminary injunctions under the lanham act.” · 5 citing courts
5
GREENWorthy v. Collagen Corp., 967 S.W.2d 360 (Tex. 1998).
cites § 814.1 2×cited by 68 cases
Where it cites § 814.1
“§ 360e(b)(l)(A); 21 C.F.R. § 814.1 (c)(1) (1997). A second is for devices “substantially equivalent” to devices marketed before May 28, 1976.”
The case’s holding
State law claims alleging liability despite a medical device's adherence to FDA-approved standards are preempted by federal requirements.
Later courts cite it for
“while a federal requirement would ordinarily not preempt general state common law requirements such as a duty of care or a duty to warn in the abstract, a federal requirement would preempt a particularized application of such duties that imposed a specific 'standard of care or behavior' different or in addition to the federal requirement.” · 3 citing courts
6
GREENGomez v. St. Jude Med. Daig Div. Inc., 442 F.3d 919 (5th Cir. 2006).
cites § 814.1 1×cited by 113 cases
Where it cites § 814.1
“§ 360e(b)(1)(A); 21 C.F.R. § 814.1 (c)(1)). Second, devices that are “substantially equivalent” to a preexisting medical device are exempt from the PMA process and instead subject to a streamlined approval process.”
The case’s holding
State-law design, warning, and training claims for medical devices are preempted if they displace the FDA's exclusive role or impose requirements that parallel or enforce federal regulations.
Later courts cite it for
“the district judge properly limited gomez's negligence claims to a claim that the medical device used in her surgery was defectively manufactured because it did not comply with the fda-approved specifications.” · 3 citing courts
7
GREENCharlotte Kennedy v. Collagen Corp., 67 F.3d 1453 (9th Cir. 1995).
cites § 814.1 2×cited by 50 cases
Where it cites § 814.1
“§ 360e; 21 C.F.R. § 814.1 (c). In order to attain premarket approval, the manufacturer of a Class III device must submit all of its information on any investigations concerning the device’s safety or effectiveness, a statement of the intended use of the product, a description of…”
The case’s holding
State common law claims of general applicability are not preempted by the Medical Device Amendments because they do not constitute specific requirements applicable to a particular device.
Later courts cite it for
“pre-market approval is supposed to benefit consumers, not create a rose garden, free from liability, for manufacturers.” · 2 citing courts
8
GREENHenson v. Dep't of Health & Human Servs., 892 F.3d 868 (7th Cir. 2018).
cites § 814.1 1×cited by 26 cases
Where it cites § 814.1
“He was not satisfied with the response, so he sued, alleging that the agency failed to satisfy its obligations under the Freedom of Information Act.”
The case’s holding
A district court lacks a sufficient factual basis for denying a motion to compel if it fails to review privilege logs or conduct an in camera inspection of documents (5).
Later courts cite it for
“reasonably detailed, sets forth the search terms used in electronic searches and the kind of search performed by the agency, and avers that all files likely to contain responsive documents were searched.” · 5 citing courts
9
GREENWalker v. Johnson & Johnson Vision Prods., Inc, 552 N.W.2d 679 (Mich. Ct. App. 1996).
cites § 814.1 2×cited by 26 cases
Where it cites § 814.1
“§ 360e; 21 CFR 814.1. The fact that the premarket approval process involves specific requirements, see 21 CFR 814, 820, must not be confused with the premarket approval requirement itself acting as a specific requirement.”
The case’s holding
Federal premarket approval of a Class III medical device does not expressly preempt state products liability claims against the manufacturer for negligent design, failure to warn, or breach of implied warranty.
Later courts cite it for
“should defer to a federal agency's construction of the statute unless the agency's interpretation is unreasonable.” · 3 citing courts
10
GREENRosci v. AcroMed, Inc., 669 A.2d 959 (Pa. Super. Ct. 1995).
cites § 814.1 2×cited by 26 cases
Where it cites § 814.1
“They include Zyderm, as well as pacemakers, heart valves and replacement joints.”
The case’s holding
The learned intermediary doctrine does not bar claims for breach of express warranty, and federal medical device regulations do not preempt express warranty claims.
Later courts cite it for
“the intended 'user' in a case involving a prescription drug or device is, of course, the prescribing physician.” · 2 citing courts
11
GREENSteele v. Collagen Corp., 54 Cal. App. 4th 1474 (Ct. App. 1997).
cites § 814.1 2×cited by 24 cases
Where it cites § 814.1
“§ 360e(b)(1)(A); 21 CFR § 814.1 (c)(1). Second, to prevent manufacturers of grandfathered devices from monopolizing the market while new devices clear the PMA hurdle, and to ensure that improvements to existing devices can be rapidly introduced into the market, the Act also…”
The case’s holding
State law claims regarding device safety and effectiveness are preempted when they impose requirements different from or in addition to federal requirements resulting from the PMA process.
Later courts cite it for
“while the design or labeling of a device may be changed to enhance the safety without prior approval from the fda, the manufacturer must submit to the fda a pma supplement and obtain acknowledgment from the fda of receipt of the supplement. ( 21 c.f.r. 814.39 (1996).) the device is still subject to withdrawal from the market if the fda determines any changes have rendered it unsafe or the labeling inadequate.” · 2 citing courts
12
GREENBarbara MITCHELL & Gregory Mitchell v. COLLAGEN Corp., 126 F.3d 902 (7th Cir. 1997).
cites § 814.1 1×cited by 95 cases
Where it cites § 814.1
“21 C.F.R. § 814.1 (c)(1). Second, those devices that are “substantially equivalent” to grandfathered products are exempt from the PMA process until the FDA initiates and completes the PMA process for such products.”
The case’s holding
The FDA premarket approval process constitutes a specific federal regulation that preempts state law claims imposing requirements different from or in addition to federal standards.
Later courts cite it for
“constitutes approval of the product's design, testing, intended use, manufacturing methods, performance standards and labeling.” · 5 citing courts
13
GREENSowell v. Bausch & Lomb, Inc., 230 A.D.2d 77 (N.Y. App. Div. 1st Dep't 1997).
cites § 814.1 2×cited by 20 cases
Where it cites § 814.1
“The general rule applicable to distributors of Class III medical devices requires them to obtain premarket approval (PMA) of the device before marketing it (21 USC § 360e; 21 CFR 814.1 [c]; 860.3 [c] [3]). Before a PMA will be granted, the Federal Food and Drug Administration…”
Later courts cite it for
“while a pma review is considerably more rigorous and detailed than the pre-market notification process at issue in med-tronic, it is, in fact, no more 'specific' a requirement.” · 3 citing courts
14
GREENBlanco v. Baxter Healthcare Corp., 158 Cal. App. 4th 1039 (Ct. App. 2008).
cites § 814.1 1×cited by 31 cases
Where it cites § 814.1
“§ 360c(a)(l)(C); see 360e(d)(2); 21 C.F.R. § 814.1 et seq. (2007).) *1043 The MDA requires the PMA application to contain the following information: full reports on investigations concerning whether the device is safe and effective; statements of the device’s components,…”
The case’s holding
State common law tort claims challenging the manufacture or labeling of a device approved through FDA premarket approval are preempted by the Medical Device Amendments because they impose different requirements.
Later courts cite it for
“the fact that the fda implemented a class i recall of the medical device does not alter our conclusion that plaintiffs claims are preempted.” · 1 citing court
15
GREENFemrite v. Abbott Nw. Hosp., 568 N.W.2d 535 (Minn. Ct. App. 1997).
cites § 814.1 2×cited by 17 cases
Where it cites § 814.1
“See 21 C.F.R. § 814.1 (a), (c) (1996). To obtain premarket approval, a manufacturer must submit extensive preclinical and clinical data to the FDA demonstrating that the device is safe and effective.”
Later courts cite it for
“belongs to the class of persons that the regulation is intended to protect,” · 3 citing courts
16
GREENGoodlin v. Medtronic, Inc., 167 F.3d 1367 (11th Cir. 1999).
cites § 814.1 1×cited by 59 cases
Where it cites § 814.1
“§ 360e(b)(l)(A); 21 C.F.R. § 814.1 (c)(1). A manufacturer may also seek approval of a new device by showing that the new device is the "substantial equivalent” of such a grandfathered device.”
The case’s holding
FDA premarket approval of a medical device does not impose an ascertainable federal requirement that preempts state law product liability claims.
Later courts cite it for
“neither the fda's actual review of a device and its supporting information nor the agency's eventual approval of the device imposes any ascertainable requirement upon the device.” · 4 citing courts
17
REDLora Lohr v. Medtronic, Inc., 56 F.3d 1335 (11th Cir. 1995).
cites § 814.1 1×cited by 44 cases
Reversed in part by Medtronic, Inc. v. Lohr (1996): the U.S. Supreme Court's own opinion in this case ("VII Accordingly, the judgment of the Court of Appeals is reversed insofar as it held that any of the claims were preempted an…
Where it cites § 814.1
“§ 360e(b)(l)(A); 21 C.F.R. § 814.1 (c)(1) (1994). Second, the MDA contains an investigational device exemption (IDE) for new devices under clinical investigation to determine their safety or effectiveness.”
The case’s holding
The Medical Device Amendments do not preempt state law negligent design or strict liability claims for devices cleared through the 510(k) substantial equivalence process.
Later courts cite it for
“preemption under the mda cannot be defeated by a common lawsuit alleging a violation of the statutory standards” · 2 citing courts
18
GREENMills v. Warner-Lambert Co., 581 F. Supp. 2d 772 (E.D. Tex. 2008).
cites § 814.1 1×cited by 17 cases
Where it cites § 814.1
“§ 360e(b)(l)(A); 21 C.F.R. § 814.1 (c)(1). However, the review focused only on equivalence — not safety or efficacy.”
Later courts cite it for
“only reasonable inferences in favor of the nonmoving party can be drawn from the evidence.” · 7 citing courts
19
GREENLakie v. SmithKline Beecham, 965 F. Supp. 49 (D.D.C. 1997).
cites § 814.1 1×cited by 33 cases
Later courts cite it for
“pass on the merits of the expert's scientific conclusions ... , and it must refrain from 'evaluating the credibility of opposing experts and the persuasiveness of competing studies.” · 3 citing courts
20
GREENBurgstahler v. AcroMed Corp., 670 A.2d 658 (Pa. Super. Ct. 1995).
cites § 814.1 2×cited by 9 cases
Where it cites § 814.1
“They include Zyderm, as well as pacemakers, heart valves and replacement joints.”

Show all 44 citing cases (list view) →

The flag is Syfertize’s treatment of the citing case itself, not of the statute. “Where it cites” is the passage in the opinion; the holding is a summary of the whole case and may concern another point. Annotations are extracted automatically from the opinions in the Syfert caselaw corpus.

Citing cases by year
199420092025

One bar per year. Tallest: 7 cases in 1997. These are opinions in the Syfert collection, which holds more of some courts’ recent opinions than their older ones, so a rise can reflect what the collection holds and not more litigation.

By court
11th Cir.6Ill. App. Ct.47th Cir.38th Cir.29th Cir.2Cal. Ct. App.2D. Md.2Pa. Super. Ct.2

The 8 courts with the most citing cases, of 29 courts in all.

By subsection
(c)1 case
D'Agostino v. EV3, Inc., 845 F.3d 1 (1st Cir. 2016).“See 21 C.F.R, § 814.1(c). During that process, the device manufacturer supplies the FDA with extensive information regarding the device — including its design, manufacturing, packing, labeling, and testing — to satisfy the agency that the device is safe and effective.”
(c)(1)2 cases
Carol Jean Brooks v. Howmedica, Inc., 273 F.3d 785 (8th Cir. 2001).
Brooks v. Howmedica, 273 F.3d 785 (8th Cir. 2001).

Show all 44 citing cases (list view) →

Enactment and amendments

Syfert holds no separate history line for this section. Where this code prints a source or history note, it appears with the text, usually at the end.

Versions

Edition shown: eCFR text as of Sept. 29, 2026. Syfert holds no earlier or later version of this section.

C.F.R. Home  |  Search C.F.R.  |  Search cases for this section  |  syfert.com